[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • A similar pattern was observed for risk of cutaneous melanoma (SIR: CLL/SLL = 1.92, FL = 1.60, DLBCL = 1.06; P(Diff) = .004).
  • Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


2. Sokołowska-Wojdyło M, Trzeciak M, Roszkiewicz J: 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma. Dermatol Reports; 2010 Aug 31;2(2):e12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma.
  • The primary cutaneous lymphomas are often indolent but difficult to treat.
  • In the early stages psoralen and ultraviolet-A therapy is the standard treatment whereas at the tumor stage chemotherapy (e.g. pegylated doxorubicin) is often used for debulking.
  • The purine analog 2-chlorodeoxyadenosine (2CdA) acts in non-Hodgkin's lymphoma and has been used in our center for the treatment of advanced primary cutaneous T-cell lyphomas (CTCL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25386249.001).
  • [ISSN] 2036-7392
  • [Journal-full-title] Dermatology reports
  • [ISO-abbreviation] Dermatol Reports
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC4211472
  • [Keywords] NOTNLM ; 2-chlorodeoxyadenosine (2CdA) / Sézary syndrome / cutaneous T-cell lymphoma / mycosis fungoides / side effect. / treatment
  •  go-up   go-down


3. Chao-Lo MP, King-Ismael D, Lopez RA: Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep; 2008 Oct 11;2(3):31-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case.
  • Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare type of non-Hodgkin's lymphoma comprising approximately 0.9-9.0% of all cutaneous lymphomas.
  • Immunohistochemistry revealed that these atypical cells are anaplastic lymphoma kinase (ALK) positive, CD30+, CD3-, CD20- and epithelial membrane antigen (EMA) negative.
  • Short course CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) chemotherapy resulted in total resolution of skin lesions; however, recurrence was noted 12 months after treatment.
  • She then underwent radiotherapy and achieved complete remission.Because the clinical presentation of PCALCL can be variable, a high index of suspicion is necessary in patients presenting with chronic plaques and nodules unresponsive to topical or oral medications.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 2):857-61 [10321635.001]
  • [Cites] Eur J Pediatr. 2008 Jan;167(1):111-3 [17219127.001]
  • [Cites] J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):793-6 [11050582.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Dermatopathol. 2003 Apr;25(2):142-7 [12652196.001]
  • [Cites] J Am Acad Dermatol. 2003 Dec;49(6):1049-58 [14639383.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2004 May-Jun;70(3):168-71 [17642599.001]
  • [Cites] Blood. 2007 Jul 15;110(2):479-84 [17339420.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Dec;17(6):1319-32, vii-viii [14710887.001]
  • [Cites] Pediatr Dermatol. 2004 May-Jun;21(3):212-7 [15165197.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1202-7 [15214912.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1):103-10 [15243534.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):221-6 [16104878.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:323-30, 513 [17124079.001]
  • [Cites] Am J Dermatopathol. 2000 Oct;22(5):422-8 [11048978.001]
  • (PMID = 21886709.001).
  • [ISSN] 1898-7249
  • [Journal-full-title] Journal of dermatological case reports
  • [ISO-abbreviation] J Dermatol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3157779
  • [Keywords] NOTNLM ; lymphomatoid papulosis / lymphoproliferative disorders / mycosis fungoides / primary cutaneous CD30 positive large T cell lymphoma / primary cutaneous anaplastic large cell lymphoma
  •  go-up   go-down


Advertisement
4. Scarisbrick JJ, Child FJ, Clift A, Sabroe R, Whittaker SJ, Spittle M, Russell-Jones R: A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol; 2001 May;144(5):1010-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
  • BACKGROUND: The combination of fludarabine and cyclophosphamide shows synergistic toxicity in vitro and has been used to treat nodal non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukaemia.
  • OBJECTIVES: To test the efficacy of this combination in 12 patients with cutaneous T-cell lymphoma (CTCL).
  • Five with SS had a response (one had a complete clinical response and four a partial response) and one patient with MF had stable disease.
  • Six patients had treatment withdrawn, five due to bone marrow suppression and one due to progressive disease.
  • No difference in pretrial parameters were found in those who had treatment withdrawn and those who tolerated at least three courses.
  • As with other multiagent chemotherapy regimens, bone marrow toxicity is a common and severe side-effect.
  • These data suggest that this regimen should be considered palliative and should be reserved for patients with refractory disease without bone marrow suppression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Mycosis Fungoides / drug therapy. Pilot Projects. Sezary Syndrome / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11359390.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


5. Visco C, Medeiros LJ, Jones D, Smith T, Rodriguez MA, McLaughlin P, Romaguera J, Cabanillas F, Sarris AH: Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. Ann Oncol; 2002 Aug;13(8):1290-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
  • BACKGROUND: The aim of this study was to explore the association between extent of cutaneous involvement, presenting features and progression-free survival (PFS) in patients with primary cutaneous non-Hodgkin's lymphoma (PCNHL) of aggressive histology.
  • METHODS: Previously untreated patients with localized or extensive PCNHL of aggressive histology, treated with combination chemotherapy, but excluding lymphoblastic lymphoma and mycosis fungoides and its variants, were reviewed retrospectively.
  • Median age was 52 years (range 25-81 years), and disease was localized and extensive in 37 and 16 patients, respectively.
  • Twenty-four patients had diffuse large B-cell lymphoma, nine had grade 3 follicular lymphoma, 13 had peripheral T-cell lymphoma (PTCL; not otherwise specified) and seven had anaplastic large cell lymphoma (WHO classification).
  • CONCLUSIONS: PTCL and elevated serum LDH level, but not extent of cutaneous involvement are associated with inferior PFS in aggressive PCNHL treated with combination chemotherapy.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181254.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


6. Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M: Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Arch Dermatol Res; 2009 Oct;301(9):689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma.
  • The case of a 44-year-old man with a primary cutaneous large B-cell non-Hodgkin's lymphoma of the scalp is reported.
  • His mother died of gastric lymphoma and his sib brother is in a 20-year remission of T-cell lymphoma.
  • The histopathology and immunohistochemistry performed in April 2006 indicated a bcl-6+, MUM- and bcl-2-, primary cutaneous follicle center B-cell non-Hodgkin's lymphoma, with an aggressive transformation to a diffuse large B-cell lymphoma.
  • Bone marrow biopsy and CT chest, abdomen, and pelvis were negative for systemic lymphoma.
  • The protracted indolent phase of the disease, the familial history of lymphoma, the histological aggressive features and the patient's excellent response to immunochemotherapy all contribute to a very unusual manifestation of this disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, Neoplasm / metabolism. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunotherapy. Injections, Intravenous. Male. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rituximab. Treatment Outcome. Vesicular Transport Proteins / metabolism. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495780.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / BCL2L15 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TRAPPC1 protein, human; 0 / Vesicular Transport Proteins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Venizelos ID, Tatsiou ZA, Mandala E: Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Dec;17(4):177-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review.
  • T-cell-rich B-cell lymphoma (TCRBCL) is a recently recognized B-cell lymphoma variant, characterized by a minor population of neoplastic B-cells existing in a background of predominant reactive T-lymphocytes.
  • It is a rare entity, accounting for approximately 1 to 2% of all non-Hodgkin's lymphomas.
  • Primary cutaneous TCRBCL is an extremely rare lymphoma and only 16 cases have been documented thus far in the medical literature.
  • A complete surgical excision of the skin lesion and systemic chemotherapy seems to have been effective because the patient is disease-free 2 years after the initial diagnosis was made.
  • Because of its rarity, it is especially important to make the correct diagnosis using the appropriate immunohistochemical stains and apply the proper therapy.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, B-Cell / pathology. Scalp / pathology. Skin Neoplasms / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104743.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Slovenia
  • [Number-of-references] 25
  •  go-up   go-down


8. Mukesh M, Shuttleworth D, Murray P: Primary cutaneous Hodgkin's lymphoma. Clin Exp Dermatol; 2009 Dec;34(8):e673-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous Hodgkin's lymphoma.
  • Cutaneous involvement in Hodgkin's lymphoma is an uncommon but well-recognized condition that usually occurs with advanced-stage disease.
  • Primary cutaneous Hodgkin's disease (PCHD) is exceedingly rare, with only a few reported cases.
  • We report a case of a man treated with combination systemic chemotherapy for PCHD, and review the available literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817768.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 10
  •  go-up   go-down


9. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F: Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol; 2001 Jan 15;19(2):398-405
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.
  • PURPOSE: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin's lymphoma (PCNHL).
  • PATIENTS AND METHODS: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I.
  • Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient.
  • After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma.
  • The first failure was exclusively cutaneous in 50% of relapses.
  • For the 44 treated patients, progression-free survival (PFS; actuarial +/- SE) was 61% +/- 7% and survival was 58% +/- 9% at 12 years.
  • For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% +/- 12% (P = .0003) versus 0% after radiotherapy; survival was 77% +/- 12% versus 25% +/- 22% (P = 004), respectively.
  • For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% +/- 11% and survival 70% +/- 18%.
  • CONCLUSION: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients.
  • Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy.
  • Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208831.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


10. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L: Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol; 2005 May;52(5):847-53
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary cutaneous B-cell lymphoma with rituximab.
  • Intravenous administration of rituximab has been used for the treatment of patients with low-, intermediate-, and high-grade B-cell non-Hodgkin's lymphomas and is a registered treatment modality for this indication.
  • Treatment of primary cutaneous B-cell lymphoma (CBCL) with intralesionally or systemically administered rituximab has been described only in a few cases.
  • OBJECTIVE: Our purpose was to assess the efficacy of rituximab in the treatment of CBCL.
  • Complete remission could be observed in 6 of 7 patients after 1 to 8 cycles of intralesional treatment with rituximab.
  • In one patient one of two lesions showed a partial remission after 4 cycles of treatment, whereas the second showed complete remission.
  • A local recurrence was observed in one patient after 27 months of follow-up and in two patients recurrences developed at other body sites after 12 and 14 months of follow-up.
  • CONCLUSION: Rituximab therapy is a well-tolerated and effective treatment for primary CBCL.
  • In comparison to intravenous administration, intralesional application of the drug allows the use of lower dosages.
  • Intralesional therapy with rituximab deserves further investigation and comparison to systemic administration of the drug in controlled multicenter studies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858476.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


11. Khalifeh I, Hughey LC, Huang CC, Reddy VV, Sellheyer K: Solitary plaque on the scalp as a primary manifestation of Hodgkin lymphoma: a case report and review of the literature. J Cutan Pathol; 2009 Oct;36 Suppl 1:80-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plaque on the scalp as a primary manifestation of Hodgkin lymphoma: a case report and review of the literature.
  • Cutaneous Hodgkin lymphoma is infrequent and typically occurs after extensive involvement of the lymph nodes.
  • The condition decreased significantly in incidence in the past two decades, likely owing to the new treatment protocols composed of chemotherapy, radiotherapy and stem cell transplantation.
  • Nevertheless, recognition of this uncommon but significant disease manifestation is important from a prognostic and therapeutic perspective.
  • We are sharing a recent case of Hodgkin lymphoma where the primary presentation appeared as a solitary plaque on the left side of the occipital scalp, clinically suspected to represent a ruptured follicular cyst.
  • Histological assessment revealed Hodgkin lymphoma affecting the skin.
  • However, two enlarged lymph nodes were identified in the mediastinum and were positron emission tomography avid.
  • The patient underwent systemic treatment without further histopathological examination of these two lymph nodes.
  • Not being clear if these enlarged two lymph nodes were related to his cutaneous disease or not, we cannot be sure if the patient was afflicted either by primary cutaneous Hodgkin lymphoma or by secondary cutaneous involvement because of hematogenous spread.
  • In either case, primary or secondary cutaneous Hodgkin disease is an extreme rarity.
  • [MeSH-major] Hodgkin Disease / pathology. Scalp / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775396.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 32
  •  go-up   go-down


12. Anghel G, Pulsoni A, De Rosa L: Primary cutaneous follicle center cell lymphoma and limited stage follicular non-Hodgkin's lymphoma: a comparison of clinical and biological features. Leuk Lymphoma; 2002 Nov;43(11):2109-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous follicle center cell lymphoma and limited stage follicular non-Hodgkin's lymphoma: a comparison of clinical and biological features.
  • Primary cutaneous follicular lymphoma (PCFL) and nodal follicular lymphoma (NFL) are different entities, which, nevertheless, exhibit common features.
  • A group of 22 consecutive patients with PCFL presenting with single or multiple cutaneous lesions was compared to a group of 21 patients with limited stage NFL.
  • The histologic features were compared, as well as treatment modalities and response.
  • Treatment of PCFL consisted of restricted field radiotherapy (RT), chemotherapy (CHT) and combined modalities (CM) in 12, 5 and 5 cases, respectively.
  • The response to treatment was: 17 complete responses, CR (12 RT, 2 CHT, 3 CM), 3 partial responses, PR (1 CHT, 2 CM) and 2 non-responses, NR (2 CHT) in the PCFL group, while in the NFL group 18 patients attained CR (13 RT, 4 CHT, 1 CM) and 3 PR (3 CHT).
  • In conclusion, despite histologic (higher proportion of large cells) and biologic differences, cutaneous and limited stage NFL show similar responses to treatment, with similar relapse rates, EFS and OS.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Follicular / classification. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12533035.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Terao H, Kiryu H, Ohshima K, Kikuchi M, Furue M: Cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma preceded by Hodgkin's disease. J Dermatol; 2000 Mar;27(3):170-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma preceded by Hodgkin's disease.
  • A 38-year-old female was diagnosed as Hodgkin's disease of the axillar lymph nodes, nodular sclerosis type, as evidenced by the presence of Reed-Sternberg cells positive for CD30 and CD15 and negative for CD3, CD20, and CD45.
  • She achieved complete remission after combination chemotherapy.
  • These findings were mostly compatible with CD30 (Ki-1)-positive anaplastic large cell lymphoma (Ki-1 lymphoma).
  • Our case is considered to be cutaneous Ki-1 lymphoma preceded by Hodgkin's disease.
  • [MeSH-major] Antigens, CD30 / analysis. Antigens, Neoplasm / analysis. Hodgkin Disease / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Biopsy. Female. Humans. Lymph Nodes / pathology


14. Kirova YM, Dumont J, Validire P, Vincent-Salomon A, Decaudin D, Clough CB, Servois V, Savignoni A, Fourquet A: Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis. J Clin Oncol; 2004 Jul 15;22(14_suppl):6722

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of localized primary breast B-cell Non-Hodgkin's Lymphoma: Role of CNS prophylaxis.
  • : 6722 Background:to evaluate the results of combined treatment modality with doxorubicin-based chemotherapy (C), locoregional radiotherapy (RT) and CNS prophylaxis in NHL of the breast.
  • METHODS: From 1984 to 1999, 20 female pts with diffuse large B-cell lymphoma of the breast, were treated at the Curie Institute.
  • The C protocols were: time-modified CHOP: D1, 10, 20,35,50,65 (n=14) or MACOP-B variant (n=3), both with IT MTX and araC.
  • Total dose was 40 Gy in 20-22 fractions using megavoltage photons.
  • RT to CNS (18 Gy/10 fr.) was delivered in the same time.
  • The CR rate was 100% at the end of treatment.
  • Relapses included lymph nodes (3); LN+breast (2); cutaneous (1), GI (1).
  • CONCLUSIONS: CNS prophylaxis by IT C and CNS RT could prevent CNS relapses in pts with primary breast LNH.
  • Though all pts had CR following treatment, relapses occurred in 40% of the pts including late relapses.
  • Prospective studies are needed to improve the long-term results and define the modality of CNS prophylaxis in this rare but aggressive disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Murtaza B, Khan NA, Nadeem A, Khan S, Saeed S: Multiple perineal sinuses in non-hodgkin's lymphoma. J Coll Physicians Surg Pak; 2007 Oct;17(10):640-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple perineal sinuses in non-hodgkin's lymphoma.
  • Biopsy of the inguinal lymph node revealed follicular B-cell non-Hodgkin's lymphoma while the biopsy of the sinuses was non-specific.
  • It was diagnosed as a case of primary nodal NHL with secondary cutaneous manifestations of multiple perineal sinuses (paraneoplastic dermatosis).
  • After two courses of chemotherapy, the discharge from the sinuses disappeared and the lesions healed by scarring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999862.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


16. Scarisbrick JJ, Child F, Spittle M, Calonje E, Russell-Jones R: Systemic Hodgkin's lymphoma in a patient with Sézary syndrome. Br J Dermatol; 2000 Apr;142(4):771-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic Hodgkin's lymphoma in a patient with Sézary syndrome.
  • We report a case of a 71-year-old male with Sézary syndrome diagnosed in 1996 who subsequently developed systemic Hodgkin's lymphoma.
  • His only past treatment was bath psoralen plus ultraviolet A.
  • He has since been treated with multiagent chemotherapy (ChlVPP/PABLOE) which induced a remission in his Hodgkin's disease.
  • Eighteen months later he remains in remission from Hodgkin's disease but the Sézary syndrome remains active.
  • He has also developed a squamous cell carcinoma on the upper lip.
  • Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by a malignant proliferation of CD4-positive cells in the skin and peripheral circulation.
  • Immunosuppression is known to be associated with an increased rate of malignancies and this may account for the occurrence of Hodgkin's disease and squamous cell carcinoma in this patient with Sézary syndrome.
  • [MeSH-major] Carcinoma, Squamous Cell. Hodgkin Disease. Lip Neoplasms. Neoplasms, Multiple Primary. Sezary Syndrome. Skin Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immune Tolerance / immunology. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792230.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


17. Aboulafia DM: Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am J Clin Oncol; 2001 Jun;24(3):237-40
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
  • Primary cutaneous large B-cell lymphoma of the legs (PCLBLL) is most commonly diagnosed in the elderly, and is generally confined to the lower parts of one or sometimes both legs.
  • Despite treatment with radiotherapy, relapses and extracutaneous involvement can occur, and unlike other low-grade cutaneous-B-cell non-Hodgkin's lymphomas (NHLs), the prognosis is variable, with an estimated 5-year survival rate of 58%.
  • The patient declined recommendations to receive cytotoxic chemotherapy.
  • Instead, he was treated with anti-CD20 monoclonal therapy (rituximab) and his cutaneous lesions completely regressed during a 16-week period.
  • This report suggests that rituximab is a therapeutic option for those patients with PCLBLL who may not be good candidates to receive radiation therapy or chemotherapy.
  • Long-term follow-up and greater experience with rituximab in a variety of clinical settings will ultimately determine the appropriate role of this costly, but relatively safe, antibody-based therapy for CD20+ expressing NHLs.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11404492.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


18. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J: Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother; 2006 May;7(7):907-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bexarotene in the treatment of cutaneous T-cell lymphoma.
  • Primary cutaneous T-cell lymphomas encompass a spectrum of non-Hodgkin's lymphomas that are characterised by clonal proliferation of skin-homing malignant T lymphocytes.
  • Mycosis fungoides and the leukaemic variant Sézary syndrome, collectively referred to as cutaneous T-cell lymphomas, are the most common entities.
  • No curative therapy exists and patients ultimately develop advanced or relapsed disease that is refractory to standard treatment options.
  • Therefore, there is a great need for the development of novel emerging therapies.
  • Bexarotene is the first synthetic nuclear retinoid X receptor-selective retinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma in all stages, as both an oral capsule and a topical gel formulation.
  • Bexarotene was found to induce apoptosis in a variety of preclinical in vitro and in vivo models including cutaneous T-cell lymphoma cells, and has shown efficacy in two multi-centre, open-label Phase II - III clinical trials for early and advanced stages of cutaneous T-cell lymphoma in patients who have failed or were refractory to standard therapies.
  • New insights into the immunomodulatory function of bexarotene have indicated opportunities for combined treatment with IFN-alpha, denileukin diftitox or phototherapy.
  • This article reviews the biological properties, pharmacokinetics, clinical efficacy, safety and role of bexarotene in the treatment of cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634713.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 72
  •  go-up   go-down


19. Fierro MT, Savoia P, Quaglino P, Novelli M, Barberis M, Bernengo MG: Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. J Am Acad Dermatol; 2003 Aug;49(2):281-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
  • BACKGROUND: Rituximab, a chimeric antibody directed against CD20, has a high therapeutic value in refractory/relapsed low-grade or follicular B-cell non-Hodgkin's lymphomas as a monotherapy or in combination with polychemotherapy.
  • OBJECTIVES: We sought to evaluate the clinical activity and toxicity of a schedule foreseeing the use of intravenous rituximab preceded by single-dose cyclophosphamide in the treatment of patients with primary cutaneous B-cell lymphoma who progressed and relapsed after chemotherapy.
  • METHODS: A total of 7 patients were treated; 4 had both cutaneous lesions and nodal or visceral involvement.
  • All the patients had been previously treated with at least 1 standard chemotherapy regimen, and 4 with 2 or more, with a median response duration of 8 months.
  • Immunohistochemistry on frozen sections was performed with monoclonal antibodies directed against CD20, CD55, and CD59 before rituximab treatment.
  • RESULTS: The overall objective response rate was 85.7%, with a complete response in 5 patients; treatment was well tolerated in all cases.
  • After a median follow-up of 13 months, 2 patients showed a cutaneous relapse.
  • The response durations of the remaining patients who were disease-free are now 5, 7, 17, and 18 months.
  • CONCLUSION: Although a longer follow-up period is needed to confirm these data, our results are encouraging, particularly in terms of disease-free survival.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / metabolism. Drug Administration Schedule. Drug Therapy, Combination. Female. Flow Cytometry. Humans. Male. Middle Aged. Recurrence. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894078.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


20. Isogai R, Fukao M, Kawada A: Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy. J Dermatol; 2007 Aug;34(8):556-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a malignant lymphoma with a relatively good prognosis, consisting of CD30-positive, undifferentiated, large cells.
  • We report an elderly patient with C-ALCL which recurred after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy, but was effectively treated with the third-generation etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) regimen.
  • It is characterized by the completion of treatment in 8 weeks, its applicability on an outpatient basis, and a low incidence of cardiotoxicity and mucosal symptoms.
  • Although our patient had no side-effects during chemotherapy, patients should be carefully monitored for side-effects, especially infection.
  • In conclusion, the VNCOP-B regimen might be an effective treatment for elderly patients with good performance status, CHOP-resistant patients or patients with aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683387.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol; VNCOP-B protocol
  •  go-up   go-down


21. Hallermann C, Kaune KM, Tiemann M, Kunze E, Griesinger F, Mitteldorf C, Bertsch HP, Neumann C: High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol; 2007 Jul;86(7):509-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage.
  • In patients suffering from primary cutaneous lymphomas, secondary malignancies of various origin may develop.
  • We screened all our patients with primary cutaneous lymphomas from a 4-year recruitment period for a coexisting secondary lymphoproliferative disorder.
  • The cohort comprised of a total of 82 patients with primary cutaneous lymphomas, 62 with primary cutaneous T-cell lymphoma (CTCL), 18 with primary cutaneous B-cell lymphomas, and two with CD4+/CD56+ hematodermic neoplasm/blastic lymphomas.
  • Seven patients (8.5%) were identified with a coexisting lymphoma of a different lymphoid lineage.
  • Four patients with Sézary syndrome (SS) suffered from systemic B-cell lymphoma.
  • Two of these developed SS after chemotherapy of their B-cell lymphoma.
  • The other three patients with various types of skin lymphomas (SS, Mycosis fungoides [MF], primary cutaneous marginal zone lymphoma) developed Hodgkin's disease (hairy cell leukemia).
  • Our data indicate that patients with primary cutaneous lymphomas have an elevated risk for the development of a secondary lymphoproliferative disorder even without previous chemotherapy.
  • Possible explanations for this association include a genetic predisposition, alterations in early progenitor cells, underlying viral infections, and/or stimulation of a B-cell clone by the malignant helper T cells of the primary CTCL and vice versa.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / complications. Lymphoproliferative Disorders / complications. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Jul;86(7):517. Kaune, Matthias Kjell [corrected to Kaune, Kjell Matthias]
  • [ErratumIn] Ann Hematol. 2007 Jul;86(7):517
  • (PMID = 17340135.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Hsi ED: Pathology of primary cutaneous B-cell lymphomas: diagnosis and classification. Clin Lymphoma; 2004 Sep;5(2):89-97
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of primary cutaneous B-cell lymphomas: diagnosis and classification.
  • The skin is the second most common extranodal site for non-Hodgkin's lymphomas.
  • Primary cutaneous B-cell lymphomas are less common than T-cell lymphomas but have received much attention in the past few years.
  • However, there is still some disagreement in terminology and characteristics of these lymphomas between the World Heath Organization (WHO) classification and the European Organisation for Research and Treatment of Cancer (EORTC) proposal for primary cutaneous lymphomas.
  • This review will focus on the features of primary cutaneous B-cell lymphomas, compare and contrast areas of discordance between the WHO and EORTC systems, and outline areas for further investigation.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphoma / pathology. Lymphoma, Follicular / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Sensitivity and Specificity. Terminology as Topic. Translocation, Genetic


23. Prunier F, Revel F, Hemery Y, Glaser E, Beaufils P: [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases]. Arch Mal Coeur Vaiss; 2000 Nov;93(11):1333-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin's lymphoma presenting with arrhythmia and conduction defects. Report of 2 cases].
  • Primary cardiac lymphoma is very rare.
  • The authors report two cases, the first of a 35 year old man in whom primary cardiac lymphoma presented with ventricular tachycardia complicated secondarily by complete atrioventricular block (AVB) with pseudo-inferior wall infarction.
  • The second case was a 37 year old man with a cutaneous T cell lymphoma in whom complete AVB was the first sign of a secondary cardiac localisation of his disease.
  • The finding of cardiac lymphoma should lead to aggressive chemotherapy as soon as possible.
  • [MeSH-major] Heart Block / etiology. Heart Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11190461.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Wollina U, Graefe T, Karte K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol; 2000 Jan;42(1 Pt 1):40-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.
  • BACKGROUND: Pegylated liposomes are stable, long-circulating carriers useful for delivering doxorubicin to tumor sites with a lower toxicity than the free drug.
  • Free doxorubicin is used in several treatment protocols for non-Hodgkin's lymphoma.
  • Although pegylated liposomal doxorubicin is currently used in the treatment of Kaposi's sarcoma, no data are available for tumors, such as primary cutaneous T-cell lymphomas (CTCLs).
  • Six patients (1 woman and 5 men) aged 59 to 78 years with relapsing or recalcitrant CTCL of the mycosis fungoides type, stage (Ib/IIb), were treated with pegylated liposomal doxorubicin to induce a clinical response.
  • The drug was administered at a dosage of 20 mg m(-2) once a month.
  • The final outcome was a complete response in 4, a partial response in 1, and progressive disease in 1 patient (overall response rate, 83%).
  • There was no need of additional therapy because of side effects.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Doxorubicin / administration & dosage. Mycosis Fungoides / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Carriers. Female. Humans. Infusions, Intravenous. Liposomes. Male. Middle Aged. Pilot Projects. Polyethylene Glycols. Prospective Studies. Recurrence

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2001 Jan;44(1):149-50 [11148501.001]
  • (PMID = 10607318.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


25. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W: Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol; 2005 Jul;153(1):167-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
  • BACKGROUND: Primary cutaneous B-cell lymphomas (PCBCLs) are characterized by restriction to the skin and a variable but mostly favourable prognosis.
  • Since 1997 the recombinant, chimeric anti-CD20 antibody rituximab has been used in patients suffering from non-Hodgkin's B-cell lymphomas.
  • Different studies have shown that the effectiveness and safety in the treatment of patients with low-grade follicular lymphoma is comparable to or even higher than the standard CHOP chemotherapy.
  • So far it has been unclear whether an extended duration of therapy leads to a benefit for the patients with PCBCL.
  • OBJECTIVES: To evaluate the objective response rate, time to progression, remission quality and histological changes and to compare our data with the literature.
  • PATIENTS/METHODS: Ten patients with PCBCL [eight with follicle centre cell lymphoma (FCCL), one with marginal zone lymphoma (MZL) and one with diffuse large B-cell lymphoma of the leg (DLBCL)] were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen (rituximab) with a dosage of eight cycles, 375 mg m(-2) body surface, weekly.
  • RESULTS: The treatment regimen resulted in clinical overall response in 9 of 10 patients, in particular there were seven complete responses (70%) plus two partial responses (20%).
  • In two patients no histology was taken after treatment; one patient developed a new lesion.
  • CONCLUSIONS: Intravenous therapy with eight cycles of the anti-CD20 antibody rituximab is a non-toxic and effective treatment for a subset of patients with PCBCL (relapsed, aggressive entity, old patients, multiple lesions) with a long DR.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / immunology. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Drug Evaluation. Humans. Male. Middle Aged. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029344.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 28
  •  go-up   go-down


26. Muche JM, Gellrich S, Sterry W: Treatment of cutaneous T-cell lymphomas. Semin Cutan Med Surg; 2000 Jun;19(2):142-8
Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of cutaneous T-cell lymphomas.
  • Primary cutaneous T-cell lymphomas (CTCL), representing a heterogeneous group of non-Hodgkin's lymphomas (NHL), can be defined as clonal proliferation of skin-infiltrating T lymphocytes primarily presenting in the cutaneous compartment.
  • They show a considerable variation in clinical presentation, histology, immunophenotype, and prognosis, which is best reflected by the proposal of the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer (EORTC).
  • Due to the heterogeneity of CTCL and the lack of curative therapy regimens, multiple strategies have been proposed for the management of the different CTCL entities.
  • This includes topical application of corticosteroids, nitrogen mustard or carmustine (BCNU), radiotherapy, including total skin electron beam irradiation, photo(chemo)therapy, biological response modifiers, cytostatic chemotherapy, and combined regimens.
  • Classification, staging, and treatment modalities are discussed in detail and summarized in a stage-adapted therapy regimen for CTCL.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Lymphoma, T-Cell, Cutaneous / therapy
  • [MeSH-minor] Administration, Topical. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / administration & dosage. Combined Modality Therapy. Glucocorticoids / administration & dosage. Humans. Mechlorethamine / administration & dosage. Phototherapy / methods. Radiotherapy / methods

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10892717.001).
  • [ISSN] 1085-5629
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Glucocorticoids; 50D9XSG0VR / Mechlorethamine; U68WG3173Y / Carmustine
  • [Number-of-references] 35
  •  go-up   go-down


27. Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM: Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol; 2004 Jul;51(1):25-32
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
  • Primary cutaneous T-cell lymphomas are non-Hodgkin's lymphomas with varied clinical presentation and prognosis.
  • The most common subtypes of cutaneous T-cell lymphomas are the epidermotropic variants mycosis fungoides and Sézary syndrome.
  • Treatment of mycosis fungoides has encompassed a variety of modalities including the use of retinoids with several studies evaluating their efficacy.
  • There are no data available on cutaneous T-cell lymphomas that compare RAR and RXR retinoids.
  • There was no statistical difference in response rates (12% vs 21%), response duration (20.5 vs 7.3 months), event-free survival time (4 vs 5 months), or median survival when corrected for length of follow-up.
  • Both have favorable toxicity profiles that can be managed with medications.
  • However, the immunomodulatory effects of RAR and RXR retinoids provide a rational basis for using retinoids in combination with other biologic immune response modifiers, phototherapy, or cytotoxic chemotherapy.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Tetrahydronaphthalenes / therapeutic use. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Receptors, Retinoic Acid. Retinoid X Receptors. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15243520.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / Tetrahydronaphthalenes; 5688UTC01R / Tretinoin; A61RXM4375 / bexarotene
  •  go-up   go-down


28. Breccia M, Petti MC, D'Elia GM, D'Andrea M, Carmosino I, Alimena G: Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen. Eur J Haematol; 2002 Jan;68(1):1-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
  • The coexistence of a primary myelodysplastic syndrome (MDS) and a T-cell cutaneous non-Hodgkin's lymphoma is an extremely rare event, which has so far only been reported in a single instance in the literature.
  • We describe herein an additional case in which the lymphoid disease was combined with an MDS at the time of its evolution into acute myeloid leukemia (AML).
  • We discuss possible pathogenetic mechanisms and suggest the use of nonalkylating drugs, such as fludarabine, for the treatment of this rare association of malignancies usually characterized by a very poor response to therapy.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Lymphoma, T-Cell, Cutaneous / complications. Neoplasms, Second Primary / drug therapy. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / contraindications. Bone Marrow / pathology. Cytarabine / administration & dosage. Disease Progression. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Immunophenotyping. Male. Methotrexate / administration & dosage. Remission Induction. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


29. Eros N, Karolyi Z, Kovács A, Matolcsy A, Barna T, Kelényi G: Large B-cell lymphoma of the leg in a patient with multiple malignant tumours. Acta Derm Venereol; 2003;83(5):354-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large B-cell lymphoma of the leg in a patient with multiple malignant tumours.
  • A patient who had primary gastric B-cell non-Hodgkin's lymphoma, invasive ductal breast cancer and a basocellular carcinoma of the forehead in her medical history was studied.
  • Three years after polychemotherapy and irradiation of the breast cancer, a rapidly enlarging, ulcerated violaceous tumour developed on the patient's left leg.
  • The tumour was identified by the histopathological, immunohistochemical and immunoglobulin gene rearrangement analyses as a cutaneous large B-cell lymphoma.
  • Despite surgical excision, interferon-alpha2b treatment and chlorambucil + prednisone chemotherapy, a relapse occurred in the previously affected site, whereafter the patient received radiotherapy.
  • We discuss the clinical and histologic features and outcome of the large B-cell lymphoma of the leg, its coincidence with other diseases, and the uncommon occurrence of primary multiple malignant tumours.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Basal Cell / complications. Carcinoma, Ductal, Breast / complications. Lymphoma, B-Cell / complications. Skin Neoplasms / complications. Stomach Neoplasms / complications
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Female. Forehead. Humans. Leg Ulcer / etiology. Leg Ulcer / therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14609103.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


30. LeMaistre CF: DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications. Clin Lymphoma; 2000 Nov;1 Suppl 1:S37-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity of DAB(389)IL-2 in the treatment of cutaneous T-cell lymphoma has established the feasibility of utilizing such a targeted therapeutic in disseminated disease with acceptable toxicity.
  • Data from the phase I trial suggest that the definition of activity in other cancer types, including other non-Hodgkin's lymphomas (NHL), is warranted.
  • Three NHL patients in this study responded, two of whom had follicular lymphomas, with the third having a primary intermediate-grade B-cell NHL that was refractory to chemotherapy and stem cell transplant.
  • This patient has remained in complete remission over 3 years after treatment with DAB(389)IL-2.
  • The need for a threshold level of receptor expression, the difficulty in obtaining representative tissue, the lack of an assay that accurately reflects high-affinity receptor, and the potential difficulty of observer variability in evaluating the assays should point us toward examining response rates in cancer patients where IL-2R cannot be detected or is unknown.
  • Targeting IL-2R-expressing lymphocytes may be an effective strategy for the prevention of graft rejection and to treat or prevent graft-versus-host disease.
  • The potential utility in other autoimmune disorders is unknown, but diseases such as systemic lupus, scleroderma, and vasculitis also may be effective candidates for such ligand fusion therapy.
  • [MeSH-major] Diphtheria Toxin / therapeutic use. Immunosuppressive Agents / therapeutic use. Immunotoxins / therapeutic use. Interleukin-2 / therapeutic use. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Arthritis, Rheumatoid / drug therapy. Autoimmune Diseases / drug therapy. Clinical Trials as Topic. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Psoriasis / drug therapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707862.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Immunosuppressive Agents; 0 / Immunotoxins; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  • [Number-of-references] 19
  •  go-up   go-down


31. Greer JP, Kinney MC, Loughran TP Jr: T cell and NK cell lymphoproliferative disorders. Hematology Am Soc Hematol Educ Program; 2001;:259-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Problems with PTCL include their rarity, representing usually 10-15% of non-Hodgkin's lymphomas in the Western Hemisphere, morphologic heterogeneity, and lack of immunophenotypic markers for clonality.
  • Emphasis will be placed on extranodal T cell and natural killer (NK) cell lymphomas such as hepatosplenic lymphoma, subcutaneous panniculitis-like lymphoma and nasal/nasal type T/NK-cell lymphoma.
  • The use of ALK gene regulation in the classification of anaplastic large cell lymphoma is also reviewed. Dr.
  • The discussion focuses on LGL leukemia as an instructive model of dysregulated apoptosis causing both malignant and autoimmune disease.
  • Current management options and mechanisms of therapeutic response are also described. Dr.
  • He discusses the therapeutic options for anaplastic large cell lymphoma (ALCL), from a conservative approach for primary cutaneous ALCL to combination chemotherapy for the highly chemosensitive ALCL expressing anaplastic lymphoma kinase.
  • He reviews therapy options for the extranodal subtypes of PTCL by drawing from series in adults, pediatrics, dermatology, and the Far East.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11722988.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 241
  •  go-up   go-down


32. Sréter L: [Therapy in Hodgkin disease and non-Hodgkin lymphomas]. Orv Hetil; 2009 Apr 5;150(14):651-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy in Hodgkin disease and non-Hodgkin lymphomas].
  • [Transliterated title] A Hodgkin- és a non-Hodgkin-lymphomák kezelése.
  • The therapy of malignant lymphoproliferative diseases has changed many times in recent years.
  • Treatment strategy of Hodgkin's disease is now based on risk adaptation, including not only the results of pretreatment diagnostic and prognostic factors but also the repeated PET/CT (restaging) made in the early treatment period.
  • Possible reduction of irradiation therapy may contribute to lower the risk of secondary tumors, which are common late complications of radiochemotherapy.
  • Autologous stem cell transplantation is the therapy of choice in chemosensitive relapsing patients.
  • The complete remission rate today in Hodgkin's disease is around 85%.
  • In the heterogenic group of Non-Hodgkin Lymphomas, progression of indolent lymphomas (CLL, multiple myeloma, hairy cell leukemia, cutaneous lymphomas, etc.) is slow in case of natural course.
  • Their therapy is mostly palliative and complete remission with the latest treatment modalities is not possible.
  • Aggressive lymphomas are characterized with rapid progression and early death without treatment.Most of them respond to chemotherapy and irradiation.With an adequate therapy, 60-70% of patients reach complete remission (CR) and 40-50% of them remain in remission.
  • Using immune- and radioimmune therapy in indolent and aggressive NHL groups gives possibility to influence G0 tumor cells as well.
  • Their use in combination with classic chemotherapy leads to more complete remissions and better therapy results.
  • The introduction of routine PET/CT made the first and repeated staging of NHL more precise and contributed to more effective treatment.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasms, Second Primary / prevention & control
  • [MeSH-minor] Disease Progression. Humans. Leukemia, Hairy Cell / diagnosis. Leukemia, Hairy Cell / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Multiple Myeloma / diagnosis. Multiple Myeloma / therapy. Neoplasm Staging. Positron-Emission Tomography. Remission Induction. Stem Cell Transplantation. Tomography, X-Ray Computed. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318337.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


33. Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM: Cutaneous Hodgkin's disease. J Am Acad Dermatol; 2008 Feb;58(2):295-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous Hodgkin's disease.
  • Cutaneous Hodgkin's disease is a rare condition that usually occurs late in the course of Hodgkin's lymphoma.
  • This rare condition is thought to have decreased in incidence in recent decades, likely owing to improved treatment of patients with Hodgkin's disease, who are receiving improved chemotherapy and radiation therapy, and the advent of peripheral blood stem cell transplantation.
  • We present the case of a man who developed specific cutaneous Hodgkin's lymphoma 6 months after nonmyeloablative allogenic stem cell transplantation for his recurrent systemic disease.
  • The patient's manifestation of relapse was cutaneous dissemination of the tumor, manifested by erythematous papules and ulcerated nodules.
  • At the time of the cutaneous relapse he had minimal systemic disease.
  • This case illustrates an example of this complication of Hodgkin's disease and stresses the importance of a timely diagnosis to direct appropriate therapy.
  • A review of the literature demonstrates that the patient's lesion morphology and distribution are typical of specific manifestations of cutaneous Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222326.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement